Quest Diagnostics raised its full year 2026 revenue and earnings guidance while reporting second quarter results that showed higher sales and net income versus the prior year. The stock has returned 34.48% year to date and 37.26% over one year, closing at $233.72. A widely followed narrative fair value estimate places the shares at $239.38, implying a modest undervaluation of about 2.4%. The narrative highlights the company's role as a lab engine for consumer wellness brands and the rising importance of health data analytics as drivers of long-term earnings power, though risks remain from potential PAMA reimbursement tightening and margin pressure from higher wage and technology costs.
Quest Diagnostics IncorporatedRaised full-year guidance and reported strong Q2 results with higher sales and net income.
